Aldeyra Therapeutics — Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy · Slide 132022
Antero Midstream Partners — J.P. Morgan Global High Yield & Leveraged Finance Conference · Slide 242019